【博士論文】学術データベース

博士論文 / Efficacy of High-Dose Meropenem (6 g/day) in the Treatment of Experimental Murine Pneumonia Induced by Meropenem-resistant Pseudomonas aeruginosa メロペネム耐性緑膿菌による肺炎に対する高用量メロペネム(6g/day)の効果の検討

著者

書誌事項

タイトル

Efficacy of High-Dose Meropenem (6 g/day) in the Treatment of Experimental Murine Pneumonia Induced by Meropenem-resistant Pseudomonas aeruginosa

タイトル別名

メロペネム耐性緑膿菌による肺炎に対する高用量メロペネム(6g/day)の効果の検討

著者名

大島一浩

学位授与大学

Nagasaki University (長崎大学) (大学ID:0073) (CAT機関ID:KI000877)

取得学位

博士(医学)

学位授与番号

甲医歯薬第931号

学位授与年月日

2017-03-21

注記・抄録

High-dose meropenem (MEPM; 6 g/day) has been approved as a treatment for purulent meningitis; however, little is known regarding its in vivo efficacy in refractory lower respiratory tract infections. The purpose of this study was to evaluate the efficacy of MEPM at 6 g/day in a murine model of severe pneumonia caused by MEPM-resistant Pseudomonas aeruginosa. Experimental pneumonia induced by MEPM-resistant P. aeruginosa was treated with normal-dose MEPM (150 mg/kg of body weight, simulating a 3-g/day regimen in humans) or high-dose MEPM (500 mg/kg, simulating a 6-g/day regimen in humans). Mice treated with high-dose MEPM showed significantly restored survival relative to that of untreated mice and tended to show a survival rate higher than that of mice treated with normal-dose MEPM. The viable bacterial counts (of two clinical isolates) in the lungs decreased significantly in mice treated with high-dose MEPM from those for untreated mice (P < 0.001) or mice treated with normal-dose MEPM (P, <0.01 and <0.05). The number of inflammatory cells in the bronchoalveolar lavage fluid (BALF) was also significantly lower in mice treated with high-dose MEPM than in untreated mice. The free MEPM concentration in the epithelial lining fluid (ELF) exceeded 16 μg/ml for 85 min in mice treated with high-dose MEPM, but not for mice treated with normal-dose MEPM. Our results demonstrate that high-dose MEPM (6 g/day) might provide better protection against pneumonia caused by MEPM-resistant strains of P. aeruginosa than the dose normally administered (less than 3 g/day).

開始ページ : e02056-16

元資料の権利情報 : © American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 61(1), e02056-16; 2017

キーワード

high dose, meropenem, pharmacokinetics/pharmacodynamics, meropenem-resistant Pseudomonas aeruginosa

各種コード

NII論文ID(NAID)

500001033408

NII著者ID(NRID)
  • 8000001121742
DOI (出版社)

10.1128/AAC.02056-16

DOI

info:doi/10.1128/AAC.02056-16

本文言語コード

eng

データ提供元

機関リポジトリ / NDLデジタルコレクション

DOI

博士論文 / 長崎大学 / 医学

博士論文 / 長崎大学

博士論文 / 医学

関連著者

博士論文 / 大学

博士論文 / 学位